Recent developments on ketolides and macrolides
Related Experiment Video
Updated: Oct 4, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
1Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, USA. Yong-Jin.Wu@BMS.com
Abstract:
Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773, for the treatment of community-acquired bacterial infections caused by both macrolide- and beta-lactam-susceptible and -resistant S. pneumoniae, gram negative bacteria, and intracellular atypical pathogens. The discovery of ketolides has rekindled interest in macrolides, and recent efforts have also led to a novel class of 4''-carbamates with activity against macrolide-resistant organisms. This review is an account of recent developments on ketolides and macrolides in terms of both chemistry and antibacterial activity.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Development of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
